4.7 Article

New Horizons in cellular senescence for clinicians

期刊

AGE AND AGEING
卷 52, 期 7, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/ageing/afad127

关键词

cellular senescence; senescence-associated secretory phenotype; senolytics; senotherapeutics; human ageing; interventions; older people

向作者/读者索取更多资源

Cellular senescence is a fundamental biological mechanism contributing to aging and age-related diseases. It can be induced by various mechanisms, not just replication and telomere attrition. Senescent cells secrete inflammatory mediators that drive chronic inflammation and can convert other cells to the senescent state. Research in animal models suggests that preventing or reversing senescence may be a potential strategy against aging and age-related diseases, with interventions including exercise, nutrition, and senolytics/senostatic drugs. However, it is crucial to measure outcomes reflecting improved healthy life expectancy in clinical studies to gain trust from clinicians, patients, and the public.
Cellular senescence has emerged as a fundamental biological mechanism underpinning the ageing process and has been implicated in the pathogenesis of an increasing number of age-related conditions. Cellular senescence is a cell fate originally defined as an irreversible loss of replicative potential although it is now clear that it can be induced by a variety of mechanisms independent of replication and telomere attrition. The drivers include a persistent DNA damage response causing multiple alterations in cellular function. Senescent cells secrete a range of mediators that drive chronic inflammation and can convert other cells to the senescent state-the senescence-associated secretory phenotype. Much research to date has been conducted in animal models, but it is now clear that senescent cells accompany ageing in humans and their presence is an important driver of disease across systems. Proof-of-concept work suggests that preventing or reversing senescence may be a viable strategy to counteract human ageing and age-related disease. Possible interventions include exercise, nutrition and senolytics/senostatic drugs although there are a number of potential limitations to the use of senotherapeutics. These interventions are generally tested for single-organ conditions, but the real power of this approach is the potential to tackle multiple age-related conditions. The litmus test for this exciting new class of therapies, however, will be whether they can improve healthy life expectancy rather than merely extending lifespan. The outcomes measured in clinical studies need to reflect these aims if senotherapeutics are to gain the trust of clinicians, patients and the public.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据